Anticoagulation After Gastrointestinal Bleeding in Atrial Fibrillation
A 74-year-old man with permanent atrial fibrillation, heart failure with reduced ejection fraction (EF 35%), hypertension, and type 2 diabetes returns for review. He had a transient ischemic attack in 2019 and a duodenal ulcer bleed in 2021 that resolved with endoscopic therapy; he has had no rebleeding since. Medications are aspirin 81 mg daily, metoprolol succinate 50 mg, sacubitril/valsartan 97/103 mg twice daily, and atorvastatin 40 mg. Blood pressure is 138/82 mmHg, heart rate 78 and irregular, weight 92 kg. Creatinine is 1.9 mg/dL (eGFR 32 mL/min/1.73 m²), hemoglobin 12.8 g/dL, platelets 210,000/µL, and INR 1.1. He does not use NSAIDs and has no falls. He lives independently and manages his own medications. He asks whether he should be on a blood thinner and is worried about another gastrointestinal bleed.
1. Calculate the CHA2DS2-VASc and HAS-BLED scores. Does the prior ulcer bleed make anticoagulation inappropriate? Explain how you would use each score in this encounter.
Read the worked answer
CHA2DS2-VASc: heart failure 1, hypertension 1, age 65–74 1, diabetes 1, prior TIA 2 = 6. HAS-BLED: abnormal renal function 1, prior bleed 1, age >65 1 = 3 (his blood pressure is controlled, so no point for uncontrolled hypertension; he is not on warfarin, so no labile INR).
A score of 6 predicts a high annual stroke risk (roughly 6–9%/year) and a clear net clinical benefit from anticoagulation. HAS-BLED ≥3 flags bleeding risk but is not a reason to withhold anticoagulation; it is a prompt to correct modifiable factors. Here: stop aspirin, avoid NSAIDs, add a proton pump inhibitor, control blood pressure, screen for alcohol use, and monitor hemoglobin and renal function. His prior ulcer bleed was endoscopically treated and has not recurred; a DOAC has a lower intracranial and gastrointestinal bleeding risk than warfarin. The correct framing is that his stroke risk without therapy is higher than his rebleeding risk with careful anticoagulation.
2. Choose a specific anticoagulant and dose. Justify the dose with the renal and apixaban dose-reduction criteria, and state what you would do about his aspirin.
Read the worked answer
Apixaban 5 mg orally twice daily. Dose reduction to 2.5 mg twice daily requires at least two of: age ≥80 years, weight ≤60 kg, or creatinine ≥1.5 mg/dL. He meets only the creatinine criterion (1.9 mg/dL), so he should receive full-dose apixaban; reducing the dose without meeting criteria would lower stroke protection without a proven bleeding benefit. His eGFR of 32 mL/min/1.73 m² is acceptable for apixaban, and his Cockcroft–Gault creatinine clearance is roughly 44 mL/min, so no renal dose adjustment is needed. Warfarin with a target INR of 2–3 is a reasonable alternative if cost or coverage is an issue, but it requires monitoring and has more drug and diet interactions.
Stop aspirin. He has no coronary stent or recent acute coronary syndrome, so aspirin adds bleeding risk without a corresponding stroke-prevention benefit in atrial fibrillation. If he had a recent stent, the combination and duration would need a separate decision. Add a PPI, review over-the-counter NSAIDs, and check a CBC and creatinine at 4–6 weeks and then periodically.
3. Three months later he has epistaxis requiring nasal packing, with stable hemoglobin and no transfusion. What is your management, and what would you avoid?
Read the worked answer
This is a non-major bleed: hemoglobin is stable and he has not required transfusion. Do not stop apixaban and do not empirically reduce the dose-there is no evidence that dose reduction outside label criteria prevents bleeding, and it increases stroke risk. Manage the epistaxis locally: firm pressure, topical vasoconstrictor, packing or cautery by ENT, humidification, and saline gel. Look for reversible contributors: uncontrolled hypertension, nasal trauma, concurrent antiplatelet or NSAID use, and strong CYP3A4/P-glycoprotein inhibitors that raise apixaban levels. If bleeding recurs despite these measures, consider switching to a different anticoagulant or referring for left atrial appendage occlusion, but that is a shared decision. Check hemoglobin and renal function, reinforce adherence, and document that the anticoagulant is being continued.